Amgen Worldwide
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
オンラインリソース
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
疾患教育
重点領域
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
アムジェン株式会社（本社：東京、代表取締役社長：スティーブ・スギノ、以下「アムジェン」）、株式会社キャンサースキャン（本社：東京、代表取締役：福吉 潤、以下「キャンサースキャン」）は、2020年11月に佐倉市と締結した「骨粗鬆症疾患啓発の推進に係る連携協力（疾患啓発コモンズ）」（以下、本事業）に基づき、2021年3月から10月にかけて「二次骨折予防を目的とした骨粗鬆症疾患啓発事業」を実施し、事業報告書が佐倉市より公開されたことをお知らせいたします。
本事業では、佐倉市国民健康保険加入者（40～74歳）を対象に、過去に脆弱性骨折の既往があるにもかかわらず、骨粗しょう症の治療歴がない27名を抽出し、骨粗しょう症に関する検査や診察の受診を促す勧奨通知の送付及び効果検証を実施しました。その結果、骨粗しょう症に関する医療機関への受診率が前年比5.0倍に伸長することがわかりました2。
■背景
高齢者の骨折の多くは、骨の強度が低下し、わずかな外力により引き起こされる脆弱性骨折で、骨粗しょう症が要因となっています。また一度、脆弱性骨折を起こした骨粗しょう症の患者さんは、短期間のうちに二次骨折を引き起こすリスクが高まるとともに、骨折を原因に要介護になるリスクも高まります。千葉県佐倉市では、市民の健康寿命の延伸と医療費介護費の適正化を見据え、本事業において「骨折の医療費負荷の把握及び二次骨折予防を目的とした骨粗鬆症疾患啓発事業」を実施しました。具体的には佐倉市の国民健康保険診療報酬明細書（以下、レセプトデータ）の骨折歴、診療・治療歴、年齢などから骨折リスクの高い患者を選定し、骨粗しょう症の検査・治療を推奨する受診勧奨を行いました（図１）。
図1：二次骨折予防を目的とした骨粗鬆症の疾患啓発事業
■医療費負荷の把握
佐倉市のレセプトデータを分析したところ、大腿骨骨折を起こした方においては、一人当たりの年間医療費が骨折した前の年と比較して約160万円増加していることが示されました。一方で、再骨折リスクが高く、骨粗しょう症の治療対象と推察される大腿骨骨折または椎体骨折の既往歴がある対象者において、骨粗しょう症の治療率は44%でした。
一件の骨折を予防することの医療費インパクトは大きく、骨粗しょう症疾患啓発による骨折予防が必要と考えられます。
■疾患啓発事業の概要
| 対象者 ： | 40～74歳の佐倉市の国民健康保険被保険者のうち、過去に脆弱性骨折の既往があるにもかかわらず骨粗しょう症の治療歴がない27名 |
| 勧奨方法 ： | 骨折歴（骨折傷病名と最終診療年月）を記載した案内状、医療機関リスト、リーフレットを封入した勧奨通知を送付 |
| 勧奨資材発送日： | 2021年3月22日 |
| 効果検証期間 ： | 2021年3月から2021年10月まで |
■疾患啓発事業の結果2
本事業を通じて、脆弱性骨折の既往にかかわらず、骨粗しょう症の治療歴のない骨折リスクが高い方を対象に個別の受診勧奨通知を送付することで、骨粗しょう症の受診率の向上に繋がることがわかりました。また、通知の中に市内の居住地域にある骨粗しょう症の診断・治療に対応可能な医療機関リストを同封したことで、通知を受け取った市民の適切な医療機関への受診に繋がりました。
本報告書の詳細は、佐倉市ホームページをご参照ください。
ウェブサイト：http://www.city.sakura.lg.jp/soshiki/kenkohokenka/299/16126.html
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、現在約700人の従業員が、「To serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。詳細については
www.amgen.co.jp をご覧になるか、 www.facebook.com/amgenjapan のフォローをお願い致します。
株式会社キャンサースキャンについて
キャンサースキャンは、「人と社会を健康に」というミッションの達成に向け、データサイエンスとマーケティング、行動経済学、公衆衛生の専門知識を掛け合わせ、特定健診の受診勧奨や生活習慣病の重症化予防を目的とした受領勧奨、がん検診の受診勧奨、予防医療にかんする新たな事業開発等、日本の予防医療の推進を支援する各種事業を展開しております。
累計700以上の市町村での各種保健事業の実施支援を通じて、コミュニケーションを変え、社会の仕組みを変えながら、健康になるための行動変容にフリクションがない世界を目指しています。
ウェブサイト：https://cancerscan.jp/
Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of
Amgen. All statements, other than statements of historical fact, are statements that could be deemed
forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or
potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any
collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla®
(apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime
Therapeutics, Inc. acquisition, or the Teneobio, Inc. acquisition, as well as estimates of revenues, operating
margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory
or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and
outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our
business, and other such estimates and results. Forward-looking statements involve significant risks and
uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission
reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports
on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of
the date of this news release and does not undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
注意事項（アムジェン株式会社）
このニュースリリースに含まれている医薬品（開発中のものを含む）に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
この件に関するお問い合わせ先
アムジェン株式会社（東京）
コーポレート・アフェアーズ
TEL 03-5293-8610
株式会社キャンサースキャン
塚田 善紹
TEL 03-6420-3390
Mail info@cancerscan.jp
References